Page 226 - Vitamin D and Cancer

9 Molecular Biology of Vitamin D Metabolism and Skin Cancer 213

3. Armbrecht HJ, Boltz MA, Hodam TL (2003) PTH increases renal 25(OH)D3–1alpha
-hydroxylase (CYP1alpha) mRNA but not renal 1, 25(OH)2D3 production in adult rats. Am
J Physiol Renal Physiol 284(5):F1032–F1036
4. Armstrong BK, Kricker A (2001) The epidemiology of UV induced skin cancer. J Photochem
Photobiol B 63(1–3):8–18
5. Armstrong BK, Kricker A, English DR (1997) Sun exposure and skin cancer. Australas
J Dermatol 38(Suppl 1):S1–S6
6. Bau DT, Gurr JR, Jan KY (2001) Nitric oxide is involved in arsenite inhibition of pyrimidine
dimer excision. Carcinogenesis 22(5):709–716
7. Baudino TA, Kraichely DM, Jefcoat SC Jr et al (1998) Isolation and characterization of a
novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol
Chem 273(26):16434–16441
8. Berndt SI, Dodson JL, Huang WY et al (2006) A systematic review of vitamin D receptor
gene polymorphisms and prostate cancer risk. J Urol 175(5):1613–1623
9. Berwick M, Armstrong BK, Ben-Porat L et al (2005) Sun exposure and mortality from
melanoma. J Natl Cancer Inst 97(3):195–199
10. Bikle DD (2004) Vitamin D and skin cancer. J Nutr 134(12 Suppl):3472S–3478S
11. Bikle DD, Chang S, Crumrine D et al (2004) 25 Hydroxyvitamin D 1 alpha-hydroxylase is
required for optimal epidermal differentiation and permeability barrier homeostasis. J Invest
Dermatol 122(4):984–992
12. Bikle DD, Nemanic MK, Gee E et al (1986) 1, 25-Dihydroxyvitamin D3 production by
human keratinocytes. Kinetics and regulation. J Clin Invest 78(2):557–566
13. Bikle DD, Ng D, Oda Y et al (2002) The vitamin D response element of the involucrin gene
mediates its regulation by 1, 25-dihydroxyvitamin D3. J Invest Dermatol 119(5):1109–1113
14. Bikle DD, Pillai S (1993) Vitamin D, calcium, and epidermal differentiation. Endocr Rev
14(1):3–19
15. Bikle DD, Xie Z, Ng D et al (2003) Squamous cell carcinomas fail to respond to the prodif-
ferentiating actions of 1, 25(OH)2D: why? Recent Results Cancer Res 164:111–122
16. Blum A, Ellwanger U, Garbe C (1997) Seasonal patterns in the diagnosis of cutaneous
malignant melanoma: analysis of the data of the German Central Malignant Melanoma
Registry. Br J Dermatol 136(6):968–969
17. Boniol M, Armstrong BK, Dore JF (2006) Variation in incidence and fatality of melanoma
by season of diagnosis in new South Wales, Australia. Cancer Epidemiol Biomarkers Prev
15(3):524–526
18. Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remod-
eling. Arch Biochem Biophys 473(2):139–146
19. Brash DE, Rudolph JA, Simon JA et al (1991) A role for sunlight in skin cancer: UV-induced
p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88(22):10124–10128
20. Braun MM, Tucker MA, Devesa SS et al (1994) Seasonal variation in frequency of diagnosis
of cutaneous malignant melanoma. Melanoma Res 4(4):235–241
21. Brown AJ, Slatopolsky E (2008) Vitamin D analogs: Therapeutic applications and mecha-
nisms for selectivity. Mol Aspects Med 29(6):433–452
22. Bruch-Gerharz D, Ruzicka T, Kolb-Bachofen V (1998) Nitric oxide in human skin: current
status and future prospects. J Invest Dermatol 110(1):1–7
23. Buell JF, Hanaway MJ, Thomas M et al (2005) Skin cancer following transplantation: the Israel
Penn International Transplant Tumor Registry experience. Transplant Proc 37(2):962–963
24. Bulliard JL (2000) Site-specific risk of cutaneous malignant melanoma and pattern of sun
exposure in New Zealand. Int J Cancer 85(5):627–632
25. Bulliard JL, Cox B, Elwood JM (1994) Latitude gradients in melanoma incidence and mortality
in the non-Maori population of New Zealand. Cancer Causes Control 5(3):234–240
26. Cadet J, Voituriez L, Grand A et al (1985) Recent aspects of the photochemistry of nucleic
acids and related model compounds. Biochimie 67(3–4):277–292
27. Chen N, Nomura M, She QB et al (2001) Suppression of skin tumorigenesis in c-Jun
NH(2)-terminal kinase-2-deficient mice. Cancer Res 61(10):3908–3912